Predicting Risk of Endometrial Cancer: a multivariate prediction model with combination of lifestyle factors, clinical biochemistry, histological and genetic analysis

Portsmouth Hospitals NHS Trust0 个研究点目标入组 164 人开始时间: 2017年3月24日最近更新: 2018年2月12日

适应症

试验速览

暂无简介。

•1. Women seen in Post Menopausal Clinic at Queen Alexandra Hospital
•2. Ability to consent
•3. Aged 40 years or over
•4. Women with endometrial polyps
•5. Women with prolapse awaiting surgery
•6. Normal up to date smear
•7. Normal endometrial sampling at screening
•8. Not on prior endocrine treatment
•9. No other/second cancer in the present or past; 1. Women seen in Post Menopausal Clinic at Queen Alexandra Hospital
•2. Ability to consent
•3. Aged 40 years or over
•4. Women with endometrial polyps
•5. Women with prolapse awaiting surgery
•6. Normal up to date smear
•7. Normal endometrial sampling at screening
•8. Not on prior endocrine treatment
•9. No other/second cancer in the present or past

•Exclusion criteria as of 21/04/2017:
•1. Previous hysterectomy
•2. Breast cancer and breast cancer therapy
•3. Taking systemic hormone replacement therapy or endocrine treatment
•Original exclusion criteria:
•1. Previous hysterectomy
•2. Breast cancer and breast cancer therapy
•3. Congenital/acquired uterine anomalies
•4. Pelvic inflammatory disease, previous and active
•5. Immunodeficiency or any chronic disease
•6. Taking systemic hormone replacement therapy or endocrine treatment; Exclusion criteria as of 21/04/2017:
•1. Previous hysterectomy
•2. Breast cancer and breast cancer therapy
•3. Taking systemic hormone replacement therapy or endocrine treatment
•Original exclusion criteria:
•1. Previous hysterectomy
•2. Breast cancer and breast cancer therapy
•3. Congenital/acquired uterine anomalies
•4. Pelvic inflammatory disease, previous and active
•5. Immunodeficiency or any chronic disease
•6. Taking systemic hormone replacement therapy or endocrine treatment

发起方